“I’d be willing to bet SIO has had a look at what else is coming that will need financing when announced. I don’t think that’s too hard to figure out.”
- That would indicate no big pharma is excited enough to partner with us and put upfront non dilutive funding to run a combo trial in the near term or take on commercialization of GBM indication in the UK.
In such a scenario, SIO will squeeze the management again like they just did, particularly with the patchy history of this management in terms of delivering shareholder return.
And yet the deal was for shares at 40 cents. Forgive me for not being excited about this offering when my cost average is 65 cents after 12 years of being invested.
Glad to have you back checking in. As I told my kids a little while ago, it’s good to see someone in the institutional world finally breaking ranks with the rest. This may not seem like much but 8 million shares will provide a very HEFTY return in rather short order if MHRA is anywhere close to catching up on being timely with approval and a validation announcement regarding the June Flaskworks unit being placed in a clean room and tested comes relatively soon after. The class C suites being fitted out and inspected will be the icing on the cake that brings lots more attention ; ). Best wishes
Reading between the lines. $3 million is needed to build C suites and new FlaskWorks machines. Is it just dawned on me or you too? Those who have experienced building clean rooms and equipments know it is easy to spend tens of millions of dollars even often in a hundred millions of dollars ranges.
Is it dawned on the shorts yet?
This $3 million investment would be beautiful not just for NWBO but also for SIO too.